Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients age 12 and older with chronic graft-versus-host disease after failure of one or two systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The JAK inhibitor gains a chronic post-transplant indication distinct from its acute GVHD use.
What research teams should watch
Record whether GVHD is acute or chronic, which systemic lines failed and organ-specific baseline findings.
PRIMARY RECORDS